眼科指南

订阅

MedSci主页 / 所有栏目 / 眼科指南

玻璃体内注射技术规范——2018 年欧洲视网膜专家学会共识解读

2018-12-25 眼科新进展.2018,38(12) :1101-1104.

玻璃体内注射

玻璃体内注射( intravitreal injections，IVI) 已成为眼科最常用的治疗手段之一，能够提高许多药物在眼部治疗的效果，减少全身不良反应，是目前最有效的治疗各种视网膜和脉络膜疾病的方法。为了IVI 规范化管理操作及提高安全性，欧洲视网膜专家学会于2018 年发布了规范化IVI 技术共识。本文将对此共识进行解读，以帮助我国眼科医生提高对此技术的理解，减少不良反应。

中文标题：

玻璃体内注射技术规范——2018 年欧洲视网膜专家学会共识解读

发布机构：

发布日期：

2018-12-25

简要介绍：

玻璃体内注射( intravitreal injections，IVI) 已成为眼科最常用的治疗手段之一，能够提高许多药物在眼部治疗的效果，减少全身不良反应，是目前最有效的治疗各种视网膜和脉络膜疾病的方法。为了IVI 规范化管理操作及提高安全性，欧洲视网膜专家学会于2018 年发布了规范化IVI 技术共识。本文将对此共识进行解读，以帮助我国眼科医生提高对此技术的理解，减少不良反应。

作者： 南昌大学第一附属医院眼科 邵毅

拓展指南：与玻璃体相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=玻璃体内注射技术规范——2018 年欧洲视网膜专家学会共识解读)] GetToolGuiderByIdResponse(projectId=1, id=839511c00168a411, title=玻璃体内注射技术规范——2018 年欧洲视网膜专家学会共识解读, enTitle=, guiderFrom=眼科新进展.2018,38(12) :1101-1104., authorId=null, author=, summary=玻璃体内注射( intravitreal injections，IVI) 已成为眼科最常用的治疗手段之一，能够提高许多药物在眼部治疗的效果，减少全身不良反应，是目前最有效的治疗各种视网膜和脉络膜疾病的方法。为了IVI 规范化管理操作及提高安全性，欧洲视网膜专家学会于2018 年发布了规范化IVI 技术共识。本文将对此共识进行解读，以帮助我国眼科医生提高对此技术的理解，减少不良反应。 , cover=, journalId=null, articlesId=null, associationId=null, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Tue Dec 25 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>玻璃体内注射( intravitreal injections，IVI) 已成为眼科最常用的治疗手段之一，能够提高许多药物在眼部治疗的效果，减少全身不良反应，是目前最有效的治疗各种视网膜和脉络膜疾病的方法。为了IVI 规范化管理操作及提高安全性，欧洲视网膜专家学会于2018 年发布了规范化IVI 技术共识。本文将对此共识进行解读，以帮助我国眼科医生提高对此技术的理解，减少不良反应。</div> <div><br> </div>作者： 南昌大学第一附属医院眼科 邵毅 <div><br> </div> 拓展指南：<strong>与<font color=red>玻璃体</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=0100e1c00158810b" title="2018 临床实践指南：玻璃体内注射抗血管内皮生长因子药物治疗眼部血管疾病" target=_blank>2018 临床实践指南：玻璃体内注射抗血管内皮生长因子药物治疗眼部血管疾病</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=724321c001552199" title="2018 EURETINA专家共识建议：玻璃体内注射（更新版）" target=_blank>2018 EURETINA专家共识建议：玻璃体内注射（更新版）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=971bd1c001315562" title="2015 NICE技术评估指南：玻璃体腔内注射地塞米松治疗糖尿病性黄斑水肿（TA349）" target=_blank>2015 NICE技术评估指南：玻璃体腔内注射地塞米松治疗糖尿病性黄斑水肿（TA349）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=30e941c0009968e4" title="2013 AAO 玻璃体后脱离，视网膜裂孔并格子样变性管理指南" target=_blank>2013 AAO 玻璃体后脱离，视网膜裂孔并格子样变性管理指南</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E7%8E%BB%E7%92%83%E4%BD%93" target=_blank>有关玻璃体更多指南</a></ul>, tagList=[TagDto(tagId=51623, tagName=玻璃体内注射)], categoryList=[CategoryDto(categoryId=32, categoryName=眼科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=9313, appHits=306, showAppHits=0, pcHits=7060, showPcHits=3104, likes=137, shares=16, comments=5, approvalStatus=1, publishedTime=Sun Jan 06 20:31:18 CST 2019, publishedTimeString=2018-12-25, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun Jan 06 20:31:18 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 07:02:44 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=玻璃体内注射技术规范——2018 年欧洲视网膜专家学会共识解读)])
玻璃体内注射技术规范——2018 年欧洲视网膜专家学会共识解读
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2117388, encodeId=1f3c211e388a2, content=规范, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2c81841794, createdName=ms2150248747458913, createdTime=Fri Mar 03 17:13:16 CST 2023, time=2023-03-03, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=1198687, encodeId=f65e119868e06, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Wed Mar 02 13:05:30 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190860, encodeId=36e1119086010, content=太棒了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79c5638133, createdName=ms7000001294917993, createdTime=Mon Feb 07 22:46:00 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917116, encodeId=e93891e116a4, content=牛, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f04791673, createdName=2786945700, createdTime=Sat Jan 16 10:39:57 CST 2021, time=2021-01-16, status=1, ipAttribution=)]
    2023-03-03 ms2150248747458913 来自黑龙江省

    规范

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2117388, encodeId=1f3c211e388a2, content=规范, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2c81841794, createdName=ms2150248747458913, createdTime=Fri Mar 03 17:13:16 CST 2023, time=2023-03-03, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=1198687, encodeId=f65e119868e06, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Wed Mar 02 13:05:30 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190860, encodeId=36e1119086010, content=太棒了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79c5638133, createdName=ms7000001294917993, createdTime=Mon Feb 07 22:46:00 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917116, encodeId=e93891e116a4, content=牛, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f04791673, createdName=2786945700, createdTime=Sat Jan 16 10:39:57 CST 2021, time=2021-01-16, status=1, ipAttribution=)]
    2022-03-02 245462683

    非常感谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2117388, encodeId=1f3c211e388a2, content=规范, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2c81841794, createdName=ms2150248747458913, createdTime=Fri Mar 03 17:13:16 CST 2023, time=2023-03-03, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=1198687, encodeId=f65e119868e06, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Wed Mar 02 13:05:30 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190860, encodeId=36e1119086010, content=太棒了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79c5638133, createdName=ms7000001294917993, createdTime=Mon Feb 07 22:46:00 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917116, encodeId=e93891e116a4, content=牛, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f04791673, createdName=2786945700, createdTime=Sat Jan 16 10:39:57 CST 2021, time=2021-01-16, status=1, ipAttribution=)]
    2022-02-07 ms7000001294917993

    太棒了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2117388, encodeId=1f3c211e388a2, content=规范, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2c81841794, createdName=ms2150248747458913, createdTime=Fri Mar 03 17:13:16 CST 2023, time=2023-03-03, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=1198687, encodeId=f65e119868e06, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Wed Mar 02 13:05:30 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190860, encodeId=36e1119086010, content=太棒了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79c5638133, createdName=ms7000001294917993, createdTime=Mon Feb 07 22:46:00 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917116, encodeId=e93891e116a4, content=牛, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f04791673, createdName=2786945700, createdTime=Sat Jan 16 10:39:57 CST 2021, time=2021-01-16, status=1, ipAttribution=)]
    2021-01-16 2786945700

    牛

    0

相关指南

2018 临床实践指南：玻璃体内注射抗血管内皮生长因子药物治疗眼部血管疾病

国外眼科专家协作组（统称） · 2018-04-30

2018 EURETINA专家共识建议：玻璃体内注射（更新版）

欧洲视网膜专家学会(EURETINA,European Society of Retina Specialists) · 2018-02-01